When Ozempic was first approved in 2017, its side effect profile seemed reasonably clear: primarily nausea and gastrointestinal problems, usually temporary.
Eight years later, the story is more complex.
The FDA updated Ozempic's label four times between 2023 and 2025 — adding new warnings about gastroparesis, pulmonary issues during surgery, pancreatitis, and, most recently, vision loss. In June 2025, the European Medicines Agency (EMA) confirmed that semaglutide can cause a rare but serious eye condition. And as of June 2026, 3,763 lawsuits are pending against manufacturer Novo Nordisk for severe side effects not adequately disclosed.
I am not sharing this to alarm you. I am sharing it because you have the right to know the full data — not just what is in marketing brochures.
This article is an exclusive in-depth analysis of the documented side effects of semaglutide: what the science says, how often they occur, what's new, and how to recognize warning signs.
The Difference Between "Side Effect" and "Serious Risk"
Before we delve into the data, an important distinction. Regulators classify side effects by frequency:
- Very common: affects more than 1 in 10 users
- Common: affects between 1 in 100 and 1 in 10 users
- Uncommon: affects between 1 in 1,000 and 1 in 100 users
- Rare: affects between 1 in 10,000 and 1 in 1,000 users
- Very rare: affects fewer than 1 in 10,000 users
"Rare" does not mean "harmless". It means it happens to few people — but when it does, it can be serious or permanent.
Category 1: Very Common (More Than 1 in 10 Users)
These are the side effects that most people experience, especially in the first few weeks of treatment or after a dose increase.
Gastrointestinal Problems
These are by far the most frequent. A study published in Nature Health (2026), which analyzed over 400,000 posts from nearly 70,000 users, confirmed that 44% of users report gastrointestinal effects.
Nausea
The most common effect. It occurs because semaglutide slows stomach emptying — food stays in the stomach longer, creating that persistent feeling of sickness. It is most intense in the first 4-8 weeks and tends to decrease over time. But for some people, it never completely goes away.
Vomiting
Less frequent than nausea, but common enough to be documented in all clinical trials. It can be severe enough to cause dehydration.
Diarrhoea
Affects a significant portion of users, especially in the initial stages.
Constipation
Paradoxically, some people experience the opposite effect — gastric emptying so slow that it results in chronic constipation.
Abdominal pain and bloating
Feeling of swelling, gas, and general abdominal discomfort.
Reflux and heartburn
Delayed gastric emptying increases pressure in the stomach, which can push acid into the esophagus.
Fatigue
Fatigue emerged as one of the most frequent complaints among users, despite not being widely highlighted in traditional clinical trials. Real-world user data reveals something that clinical trials underestimated.
Category 2: Common (1 in 100 to 1 in 10 Users)
Menstrual Irregularities
Approximately 4% of users who reported side effects mentioned menstrual irregularities — discovered through the analysis of real-world user data, not the original clinical trials.
Temporary Hair Loss
Generally mild and reversible. It is associated with rapid weight loss rather than semaglutide directly.
Dizziness and Headaches
Especially in the first few weeks.
Hypoglycemia
Risk mainly when combined with insulin or sulfonylureas. For those taking only Ozempic without other diabetes medications, the risk is low.
Category 3: Rare but Serious — The Ones You Need to Know About
Pancreatitis (Inflammation of the Pancreas)
A JAMA study from October 2023 found the risk of pancreatitis to be about nine times higher among GLP-1 users compared to people taking other medications.
Pancreatitis occurs when the pancreas becomes inflamed and starts to "digest itself". It is a potentially fatal condition if left untreated.
Warning signs:
- Severe, persistent abdominal pain, often radiating to the back
- Nausea and vomiting that do not go away
- Fever
- Rapid heart rate
Gallbladder Disease
In clinical trials, cholecystitis was reported in 1.5% of patients treated with Ozempic 0.5mg and 0.4% with 1mg, compared to no cases in the placebo group. Cases of gallbladder inflammation in hospitals rose 492% during the study period.
Symptoms:
- Severe pain in the upper right quadrant of the abdomen
- Fever with chills
- Nausea
- Jaundice (yellow skin and eyes) in severe cases
Acute Kidney Injury
Kidney damage is primarily related to severe gastrointestinal effects leading to dehydration. Cases of acute kidney injury in hospitals rose 18% during the study period. Prevention is simple but critical: adequate hydration throughout treatment.
Gastroparesis — Stomach Paralysis
This is probably the most controversial side effect and has generated the most lawsuits.
The same JAMA study from 2023 found the risk of gastroparesis to be three to four times higher among GLP-1 users. Currently, there is no cure for gastroparesis.
Symptoms:
- Chronic nausea and vomiting
- Feeling full very quickly (even with little food)
- Persistent abdominal pain and bloating
- Severe heartburn and reflux
- Unintended weight loss
In October 2025, the FDA updated the label stating that Ozempic is not recommended for people with severe gastroparesis.
Eye Risk: NAION — The New Concern of 2025
NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) is a condition that causes sudden, painless vision loss in one eye due to damage to the optic nerve. It is often described as an "eye stroke".
In June 2025, after reviewing all available data, the EMA concluded that NAION is a very rare side effect of semaglutide — potentially affecting up to one in 10,000 people. Approximately 15% of people who develop NAION in one eye eventually develop the condition in the other eye as well.
Warning sign: any sudden vision loss or rapid deterioration of vision during treatment requires immediate medical attention. Treatment should be stopped if NAION is confirmed.
Diabetic Retinopathy (Worsening)
Specific to users with diabetes: in a 2-year clinical trial, more diabetic retinopathy complications occurred in patients treated with Ozempic (3.0%) compared to placebo (1.8%).
Thyroid Tumour Risk
Ozempic's label includes an FDA black box warning about the potential risk of thyroid C-cell tumours, based on animal studies.
Absolute contraindication: people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take Ozempic.
Warning signs: swelling or a lump in the neck, difficulty swallowing, unexplained hoarseness.
Risk During Surgery and Anaesthesia
Ozempic delays gastric emptying. There are reports of pulmonary aspiration in patients undergoing surgery under anaesthesia, even after correctly following pre-operative fasting. In November 2024, the FDA specifically updated the label about this risk.
Practical advice: if you are taking Ozempic and have planned surgery, always inform the anaesthetist — regardless of pre-operative fasting.
Regulatory Updates Timeline (2023-2025)
Four regulatory updates in two years is not normal. It is a sign that post-marketing data continues to reveal risks that initial clinical trials did not fully capture.
How to Manage the Most Common Side Effects
To reduce nausea:
- Eat small, frequent meals instead of large ones
- Avoid greasy, spicy, or very sweet foods
- Eat slowly and chew thoroughly
- Do not lie down immediately after eating
- Avoid alcohol (significantly worsens symptoms)
To prevent dehydration (and protect the kidneys):
- Drink water regularly throughout the day
- If vomiting is persistent, use oral rehydration solutions
- Monitor for signs of dehydration: dark urine, dizziness, dry mouth
For gradual dose titration:
The most effective strategy is to start with the lowest dose and increase very gradually. Do not rush dose progression to lose weight faster — this significantly increases side effects.
Warning Signs: When to Seek Immediate Help
Pancreatitis: severe abdominal pain radiating to the back, nausea and vomiting that do not go away.
Gallbladder: severe pain in the upper right side of the abdomen, fever, yellow skin or eyes.
Kidneys: significant reduction in urine, swollen ankles, extreme fatigue combined with persistent vomiting.
Vision: any sudden vision loss or rapid deterioration — immediate medical attention.
Thyroid: lump or swelling in the neck, unexplained hoarseness, difficulty swallowing.
Severe allergic reaction: swelling of the face, lips or throat, difficulty breathing.
Who is at Greater Risk of Serious Side Effects?
Increased risk of pancreatitis: personal history of pancreatitis, gallstones, excessive alcohol consumption, very high triglycerides.
Increased risk of kidney problems: existing chronic kidney disease, taking other nephrotoxic medications.
Absolute contraindications: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, active pancreatitis, severe gastroparesis, pregnancy or breastfeeding.
Natural Alternatives: For Those Who Prefer Another Path
If the side effects described in this article make you hesitate — or if you simply prefer a medication-free approach — there are natural ingredients with research supporting appetite regulation and metabolism.
They do not produce results as fast or dramatic as Ozempic. But they also do not carry the risk of gastroparesis, NAION, pancreatitis, or long-term medication dependence.
Kyoslim, manufactured in the European Union with DGAV authorization, combines EGCG, Guarana, L-Carnitine, Raspberry Extract, and Niacin — ingredients with research in support of metabolism and healthy weight management — as a powerful tool for those choosing a natural and sustainable approach.
FAQ
"Do gastrointestinal side effects go away over time?"
For most people, yes — they significantly decrease after 4-8 weeks. But some people continue to experience intermittent nausea throughout treatment, especially after dose increases.
"Are serious side effects reversible if I stop Ozempic?"
It depends on the effect. Most gastrointestinal effects resolve upon stopping. But some severe effects — such as severe gastroparesis or NAION — may not be reversible. That is why early attention to warning signs is so important.
"Are side effects more common with higher doses?"
Yes. Both frequency and intensity increase with dose. Gradual titration (starting with low doses and increasing slowly) is the standard strategy to minimize adverse effects.
"Should I stop taking Ozempic before surgery?"
Yes, usually. Current recommendations indicate that Ozempic should be suspended before elective surgeries under general anaesthesia, due to the risk of pulmonary aspiration. The recommended suspension time varies — consult your doctor and always inform the anaesthetist.
"How do I know if my side effects are normal or concerning?"
The general rule: nausea, mild vomiting, and abdominal discomfort in the first few weeks are expected. Anything intense, persistent, or progressively worsening should be reported to your doctor. Very severe abdominal pain, vision loss, or symptoms that do not go away are signs to seek immediate help.
Important Disclaimer: This article is for educational and informational purposes only. Ozempic (semaglutide) is a prescription medication that should be used exclusively under medical supervision. Never start, change, or stop medication without consulting your doctor. If you are taking Ozempic and experience any concerning side effects, contact your doctor or, in urgent situations, go to the emergency services.
Statements about natural supplements have not been evaluated by regulatory authorities. No supplement is intended to diagnose, treat, cure, or prevent any disease and does not replace prescribed medication.
Sources:
- FDA Label Updates: September 2023, November 2024, January 2025, October 2025
- EMA Safety Committee (PRAC) — NAION Decision, June 2025
- JAMA Research Letter — Gastroparesis and pancreatitis in GLP-1, October 2023
- Nature Health — Analysis of user-reported side effects, 2026
- JAMA Ophthalmology — NAION and semaglutide, 2024
- Health Quality Institute — California hospital analysis 2018-2022
- New England Journal of Medicine — STEP Trials, 2021
